Home › Funds › Soleus Capital Management, L.P. › AVTX

Soleus Capital Management, L.P. position in AVTX

AVALO THERAPEUTICS INC · Health Care

Soleus Capital Management, L.P. reported holding 1,654,978 shares of AVTX (AVALO THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$30.6M, representing 1.05% of its reported portfolio and ranking #28 among its reported holdings. Soleus Capital Management, L.P. has disclosed AVTX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)1.65M sh
Reported value held$30.58M
Portfolio Weight1.05%
First reportedQ4 2025
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Soleus Capital Management, L.P.'s AVTX position evolved

Soleus Capital Management, L.P. first disclosed a stake in AVTX in Q4 2025 at 441,978 shares (US$8.0M). The position peaked in Q2 2026 at 1,654,978 shares, worth US$30.6M. Across 3 filings, Soleus Capital Management, L.P. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,654,978 shares valued at US$30.6M — an increase of 1,213,000 shares quarter over quarter.. Notable position changes include a 274% increase in Q2 2026 (shares fell 17% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 441.98K $8.03M New
Q1 2026 441.98K $6.60M Hold
Q2 2026 1.65M $30.58M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About AVTX and 13F data

AVTX (AVALO THERAPEUTICS INC) is a Health Care company. 83 other funds we track also report a position in AVTX — the largest reported positions include Deep Track Capital, LP (US$66.7M), Caligan Partners LP (US$58.5M), TCG Crossover Management, LLC (US$55.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding AVTX

All AVTX fund holders →

FAQ

How long has Soleus Capital Management, L.P. held AVTX?

Soleus Capital Management, L.P. has disclosed AVTX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

What is Soleus Capital Management, L.P.'s current position in AVTX?

As of Q2 2026, Soleus Capital Management, L.P. holds 1.65M shares of AVTX (AVALO THERAPEUTICS INC), valued at $30.58M, representing 1.05% of its reported portfolio and ranking #28.

Has Soleus Capital Management, L.P. been buying or selling AVTX?

In the latest 13F filing (Q2 2026), Soleus Capital Management, L.P. increased its position in AVTX. The position peaked in Q2 2026 at 1.65M shares.

Which other funds hold AVTX?

Other major institutional holders of AVTX include Deep Track Capital, LP, Caligan Partners LP, TCG Crossover Management, LLC, among 83 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.